Evidence map›Paper›PMID 37044074›Full record

ArticleBlood purification2023

Efficacy of Double Membrane Filtration Immunoadsorption in Severe C1q-Binding Donor-Specific Antibody-Positive Acute Humoral Kidney Allograft Rejection: A Case Series.

Martin Russwurm, Tanja Maier-Giebing, Birgit Kortus-Goetze, Philipp Russ, Hermann-Josef Groene, Joachim D Hoyer

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood purification, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Martin RusswurmDivision of Nephrology, Centre for Internal Medicine, University Hospital Marburg, Marburg, Germany.
Tanja Maier-GiebingDivision of Nephrology, Centre for Internal Medicine, University Hospital Marburg, Marburg, Germany.
Birgit Kortus-GoetzeDivision of Nephrology, Centre for Internal Medicine, University Hospital Marburg, Marburg, Germany.
Philipp RussDivision of Nephrology, Centre for Internal Medicine, University Hospital Marburg, Marburg, Germany.
Hermann-Josef GroeneInstitute of Pharmacology, Philipps-University, Marburg, Germany.
Joachim D HoyerDivision of Nephrology, Centre for Internal Medicine, University Hospital Marburg, Marburg, Germany.
Philipps University of Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAcute antibody-mediated rejection (ABMR) is an important threat to renal allograft survival in the early transplant period and the major single cause of graft loss in the first postoperative year. Semi-selective immunoadsorption (IA) remains one of the commonly applied treatments in ABMR, reducing allo-reactive antibody load. Adding double filtration plasmapheresis (DFPP) to IA might enhance therapeutic efficacy by also addressing innate humoral effectors like complement factors.

methodsFour patients with ABMR were treated with DFPP + IA. Clinical, histological, and immunological data and adverse events were retrospectively collected.

resultsHere we present four high-risk treatment-refractory ABMR cases with C1q-binding donor-specific antibodies and histology of humoral rejection under treatment with DFPP + IA. While the earlier cases (within the first year after transplantation) showed marked reduction in ABMR severity and improvement of kidney function, the later cases did not respond accordingly. Late ABMR patient 1 stabilized, whereas late ABMR patient 2 did not respond to treatment.

conclusionsOur data support the consideration of DFPP + IA as a rescue treatment option in early, severe, high-risk ABMR cases in which other treatments failed.

Indexed as

Kidney TransplantationAllograftsAntibodiesComplement C1qGraft RejectionGraft SurvivalHumansKidneyRetrospective StudiesAntibodiesComplement C1qAcute antibody-mediated rejectionC1qDouble membrane filtrationImmunoadsorptionKidney transplantation

Identifiers

PMID37044074
PMCPMC10273878
OpenAlexW4365138271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.